Aspen Aerogels (ASPN)
(Delayed Data from NYSE)
$25.41 USD
+2.97 (13.24%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $25.67 +0.26 (1.02%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$25.41 USD
+2.97 (13.24%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $25.67 +0.26 (1.02%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth F Momentum D VGM
Zacks News
Aspen Aerogels (ASPN) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Aspen Aerogels (ASPN) delivered earnings and revenue surprises of -38.89% and 26.74%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Aspen Aerogels (ASPN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aspen Aerogels (ASPN) delivered earnings and revenue surprises of -19.30% and 18.13%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Aspen Aerogels (ASPN): Can Its 17.2% Jump Turn into More Strength?
by Zacks Equity Research
Aspen Aerogels (ASPN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Bear of the Day: PayPal (PYPL)
by David Bartosiak
Earnings are contracting this year but there is hope next year.
Aspen Aerogels (ASPN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aspen Aerogels (ASPN) delivered earnings and revenue surprises of -25.53% and 18.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Aspen Aerogels (ASPN) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Aspen Aerogels (ASPN) delivered earnings and revenue surprises of -66.67% and 11.86%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
All You Need to Know About Aspen Aerogels (ASPN) Rating Upgrade to Buy
by Zacks Equity Research
Aspen Aerogels (ASPN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Earnings Preview: Aspen Aerogels (ASPN) Q4 Earnings Expected to Decline
by Zacks Equity Research
Aspen Aerogels (ASPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Watsco (WSO) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Watsco (WSO) delivered earnings and revenue surprises of 18.13% and 11.75%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Orion Energy Systems, Inc. (OESX) Misses Q3 Earnings Estimates
by Zacks Equity Research
Orion Energy Systems, Inc. (OESX) delivered earnings and revenue surprises of -20% and 0.75%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Down 37.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Aspen Aerogels (ASPN)
by Zacks Equity Research
Aspen Aerogels (ASPN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Down 20.2% in 4 Weeks, Here's Why You Should You Buy the Dip in Aspen Aerogels (ASPN)
by Zacks Equity Research
Aspen Aerogels (ASPN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Aspen Aerogels (ASPN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aspen Aerogels (ASPN) delivered earnings and revenue surprises of -40.00% and 9.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Owens Corning (OC) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Owens Corning (OC) is benefitting from robust demand for residential repair and remodeling activity and insulating products. However, rising material and transportation costs are concerns.
Aspen Aerogels (ASPN) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Aspen Aerogels (ASPN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Acuity Brands (AYI) Go-To-Market Channels to Aid Q4 Earnings
by Zacks Equity Research
Strength in go-to-market channels is likely to have aided Acuity Brands' (AYI) fiscal fourth-quarter earnings.
RPM International (RPM) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
RPM International's (RPM) fiscal Q1 results are likely to reflect higher costs and expenses despite benefits from the MAP to Growth initiative along with solid housing and home improvement markets.
What Investors Should Expect From KB Home (KBH) Q3 Earnings
by Zacks Equity Research
KB Home's (KBH) fiscal Q3 results are likely to benefit from higher deliveries and pricing.
Aspen Aerogels (ASPN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aspen Aerogels (ASPN) delivered earnings and revenue surprises of 17.86% and 24.95%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Construction Stocks' Q2 Earnings on Jul 29: MLM, MAS & ASPN
by Ankita Gupta
The sector's Q2 results are likely to reflect the benefits from solid housing and R&R markets. High labor/material costs and tight supply might have been risks.
Analysts Estimate Aspen Aerogels (ASPN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Aspen Aerogels (ASPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aspen Aerogels (ASPN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aspen Aerogels (ASPN) delivered earnings and revenue surprises of -10.00% and 19.80%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Aspen Aerogels (ASPN) Q1 Earnings Expected to Decline
by Zacks Equity Research
Aspen Aerogels (ASPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for February 25th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Aspen Aerogels (ASPN) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Aspen Aerogels (ASPN) delivered earnings and revenue surprises of -53.33% and -15.42%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?